Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Anti‐infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition(2023)10.1002/jpn3.12074Source: DataRank Database

Anti‐infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease is a research paper published in Journal of Pediatric Gastroenterology and Nutrition (2023). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.74)OA: greenTopics (35)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Lisa Chi,Enju Liu,Kurtis R. Bray,Konstantinos Papamichael ORCID,Adam S. Cheifetz ORCID

Live enrichment

PubMed:38374555 PMC:PMC10883602 OpenAlex:https://openalex.org/W4390268712

NIDDK NIH HHS

Grant: P30 DK034854

NIDDK NIH HHS

Grant: T32 DK007760

NIDDK NIH HHS

Grant: K23 DK119584

FWCI

1.74

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

greenLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10883602/pdf/nihms-1947515.pdf

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/jpn3.12074

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10883602

journalhttps://doi.org/10.1002/jpn3.12074

Fields of Study

Inflammatory Bowel DiseaseLiver Diseases and ImmunityBiosimilars and Bioanalytical MethodsMedicine

MeSH Terms

InfliximabAdolescentAntibodiesChildColitis, UlcerativeCrohn DiseaseFemaleGastrointestinal AgentsHumansImmunologic FactorsProspective StudiesInflammatory Bowel DiseasesDrug MonitoringYoung Adult

Keywords

MedicineInfliximabDiscontinuationUlcerative colitisInternal medicineInflammatory bowel diseaseGastroenterologyConcomitantHazard ratioProspective cohort studySurgeryDiseaseConfidence intervalCrohn's DiseasePediatric Inflammatory Bowel DiseaseAntibodies To InfliximabInfliximab Level

Sustainable Development Goals

SDG 0: Good health and well-being